Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations
- 26 August 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 14 (9) , 789-793
Abstract
Until recently, treatment options for higher risk (HR)-myelodysplastic syndrome (MDS) patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) were limited, with hypom...Keywords
This publication has 23 references indexed in Scilit:
- The rise of apoptosis: targeting apoptosis in hematologic malignanciesBlood, 2018
- Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileOncotarget, 2018
- Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patientsLeukemia, 2015
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid LeukemiaCancer Discovery, 2014
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesLeukemia, 2014
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment FailureJournal of Clinical Oncology, 2011
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial ApoptosisMolecular Cell, 2001
- Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndromeBritish Journal of Cancer, 1998